and Spain, which have been studying the mix-and-match approach to initial shot regimens for months. This isn’t particularly surprising, given the data that have already emerged from countries such as the U.K. The 458-person NIH study showed that mix-and-match-also known as heterologous-boosting is safe and induces an increase in the relevant antibody counts, no matter the combination of vaccines.
The FDA committee is scheduled to discuss that idea, too, before this meeting ends. Meanwhile, the NIH released the results of a long-awaited (and not yet peer-reviewed) clinical trial on the “mix and match” approach to booster shots, in which people receive a dose of a different vaccine from the one they started with. (The FDA still has to authorize, and the CDC still has to recommend, any new use of boosters before they’ll be readily available.) Committee members have already voted yes on giving boosters to people over 65 and other high-risk adults who received the Moderna vaccine. An advisory committee to the FDA began a two-day meeting today to formulate recommendations for whether the agency should authorize additional doses of the Johnson & Johnson and Moderna COVID-19 vaccines. In this week’s installment of the booster chronicles, the plot is picking up.
0 kommentar(er)
